319 related articles for article (PubMed ID: 34475048)
1. P53 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma.
Sekino Y; Takemoto K; Murata D; Babasaki T; Kobatake K; Kitano H; Ikeda K; Goto K; Inoue S; Hayashi T; Taniyama D; Shigeta M; Kuraoka K; Mita K; Kaneko M; Sentani K; Oue N; Teishima J
Anticancer Res; 2021 Sep; 41(9):4287-4294. PubMed ID: 34475048
[TBL] [Abstract][Full Text] [Related]
2. CD44 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma.
Sekino Y; Takemoto K; Murata D; Babasaki T; Kobatake K; Kitano H; Ikeda K; Goto K; Inoue S; Hayashi T; Taniyama D; Shigeta M; Kuraoka K; Mita K; Kaneko M; Sentani K; Oue N; Teishima J
Anticancer Res; 2021 Oct; 41(10):4875-4883. PubMed ID: 34593435
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells.
Zhu Y; Xu L; Zhang J; Hu X; Liu Y; Yin H; Lv T; Zhang H; Liu L; An H; Liu H; Xu J; Lin Z
Cancer Sci; 2013 Aug; 104(8):1052-61. PubMed ID: 23578198
[TBL] [Abstract][Full Text] [Related]
4. Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response.
Kovacova J; Juracek J; Poprach A; Buchler T; Kopecky J; Fiala O; Svoboda M; Slaby O
Anticancer Res; 2018 May; 38(5):2961-2965. PubMed ID: 29715124
[TBL] [Abstract][Full Text] [Related]
5. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.
Cebrián A; Gómez Del Pulgar T; Méndez-Vidal MJ; Gonzálvez ML; Lainez N; Castellano D; García-Carbonero I; Esteban E; Sáez MI; Villatoro R; Suárez C; Carrato A; Munárriz-Ferrándiz J; Basterrechea L; García-Alonso M; González-Larriba JL; Perez-Valderrama B; Cruz-Jurado J; González Del Alba A; Moreno F; Reynés G; Rodríguez-Remírez M; Boni V; Mahillo-Fernández I; Martin Y; Viqueira A; García-Foncillas J
Sci Rep; 2017 Jan; 7():41371. PubMed ID: 28117391
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
[TBL] [Abstract][Full Text] [Related]
7. C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study.
Xu WH; Wang J; Huo DZ; Yin GC; Cao DL; Shi GH; Qu YY; Ye DW; Zhang HL
Med Sci Monit; 2019 Nov; 25():8984-8994. PubMed ID: 31769434
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
[TBL] [Abstract][Full Text] [Related]
9. High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.
D' Alterio C; Portella L; Ottaiano A; Rizzo M; Carteni G; Pignata S; Facchini G; Perdona S; Di Lorenzo G; Autorino R; Franco R; La Mura A; Nappi O; Castello G; Scala S
Curr Cancer Drug Targets; 2012 Jul; 12(6):693-702. PubMed ID: 22463589
[TBL] [Abstract][Full Text] [Related]
10. PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma.
Sekino Y; Hagura T; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shigeta M; Taniyama D; Kuraoka K; Sentani K; Yasui W; Matsubara A
Anticancer Res; 2020 Apr; 40(4):1943-1951. PubMed ID: 32234883
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients.
Buda-Nowak A; Kucharz J; Dumnicka P; Kuzniewski M; Herman RM; Zygulska AL; Kusnierz-Cabala B
Med Oncol; 2017 Apr; 34(4):68. PubMed ID: 28343336
[TBL] [Abstract][Full Text] [Related]
12. On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective Study.
Bolzacchini E; Pinotti G; Bertù L; Verusio C; Galli L; Mumoli N; Barbara C; Danova M; Bregni M; Artale S; Rossini C; Nigro O; Antonuzzo A; Derosa L; Torchio M; Barzaghi S; Ricci I; Suter M; Ballerio A; Vallini I; Dentali F
Clin Genitourin Cancer; 2020 Apr; 18(2):e145-e156. PubMed ID: 31889670
[TBL] [Abstract][Full Text] [Related]
13. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
14. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
15. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
Savard MF; Wells JC; Graham J; Dudani S; Steinharter JA; McGregor BA; Donskov F; Bjarnason GA; Vaishampayan UN; Hansen AR; Iafolla MAJ; Zanotti G; Huynh L; Chang R; Duh MS; Heng DYC
Oncologist; 2020 May; 25(5):422-430. PubMed ID: 31971318
[TBL] [Abstract][Full Text] [Related]
16. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.
Négrier S; Bushmakin AG; Cappelleri JC; Korytowsky B; Sandin R; Charbonneau C; Michaelson MD; Figlin RA; Motzer RJ
Eur J Cancer; 2014 Jul; 50(10):1766-1771. PubMed ID: 24768571
[TBL] [Abstract][Full Text] [Related]
17. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.
Pal SK; Sonpavde G; Agarwal N; Vogelzang NJ; Srinivas S; Haas NB; Signoretti S; McGregor BA; Jones J; Lanman RB; Banks KC; Choueiri TK
Eur Urol; 2017 Oct; 72(4):557-564. PubMed ID: 28413127
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.
Xia Y; Liu L; Xiong Y; Bai Q; Wang J; Xi W; Qu Y; Xu J; Guo J
BMC Cancer; 2017 Jan; 17(1):70. PubMed ID: 28114889
[TBL] [Abstract][Full Text] [Related]
19. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
20. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China.
Shi G; Park SH; Ren H; Xue M; Lu X; Dong P; Gao X
J Med Econ; 2018 Dec; 21(12):1150-1158. PubMed ID: 30134758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
